Monitoring of ischemia with OnZurf Probe is accepted for scientific publication

The first scientific publication with OnZurf probe "Surface microdialysis on small bowel serosa the monitoring of ischemia" is accepted for publication in the Journal of Surgical Research.

The study shows that samples collected with OnZurf Probe from the surface of the small bowel indicated the lack of oxygen already after 20 minutes. No other parameters or samples indicated early signs of reduced oxygen supply.

The article is available online.

For further information, please contact:

Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email:

Pernilla Abrahamsson, Product and business development manager Senzime AB

Tel: +46 70-37 37 472, e-post:


About Senzime

Senzime develops patient-oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. The company's share is listed on Aktietorget, Stockholm.

Explore our patient monitoring solutions

Get product details

How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.